HQ Team
June 10, 2026: A major real-world study of more than 26,000 adults in the United States has found that popular GLP-1 receptor agonist medications, prescribed for weight loss and Type 2 diabetes, may significantly reduce the risk of dangerous blood clots, emergency hospital visits, and death in patients who also live with autoimmune conditions.
Among adults with both obesity and an autoimmune disease, those taking a GLP-1 receptor agonist (GLP-1RA) medication had lower rates of emergency department visits and were less likely to experience serious cardiac events, such as stroke, pulmonary embolism, or death, compared to similar adults who were not taking these medications. The findings were published in the Journal of the American Heart Association.
The numbers are striking. People with obesity and an autoimmune disease who were on a GLP-1RA had a 17% lower risk of venous thromboembolism — blood clots forming in a vein — a 31% lower risk of pulmonary embolism, a 21% lower likelihood of emergency department visits, and a 44% decreased risk of death. The reduction in stroke risk was more modest at 13%, while the trend for heart attack risk was not statistically significant.
A high-risk and understudied population
Obesity and autoimmune disease are each associated with a higher risk of cardiovascular and blood clot events. This is the first study to examine the effects of GLP-1RAs on people with both obesity and other types of autoimmune disease, including gastrointestinal conditions such as celiac disease, skin conditions such as vitiligo, endocrine conditions such as Type 1 diabetes, and musculoskeletal diseases such as rheumatoid or psoriatic arthritis.
“This is a high-risk population, and historically we’ve had limited data to guide treatment decisions,” said lead author Amy Sheer, M.D., M.P.H., associate professor of medicine and director of the Obesity Medicine Fellowship programme at the University of Florida in Gainesville. “In this real-world analysis, we found a consistent signal toward fewer serious complications including blood clots and lower mortality among patients treated with GLP-1RA. Our research broadens the conversation around GLP-1RA.”
Research
Researchers reviewed electronic health record data for more than 26,000 adults treated in the OneFlorida+ network from 2014 to 2024. The analysis compared cardiac outcomes for 13,204 adults taking a GLP-1RA medication against 13,204 adults who did not take any GLP-1-based medication, all of whom had obesity and at least one diagnosed autoimmune condition. The average age of participants was 55 years. About 73% were women, and 53% were non-Hispanic white adults. The average body mass index at enrolment was 37 kg/m², which falls in the obesity range.
The OneFlorida+ network consists of 14 healthcare organisations and contains records for 21 million adults treated in Florida, Georgia, and Alabama. The scale of the dataset lends the findings considerable weight, though the study design — a review of health records rather than a randomised controlled trial — means it cannot definitively prove cause and effect.
Why the mortality signal matters
The most arresting finding is the 44% reduction in all-cause mortality. Independent experts were quick to flag its significance. “The 44% reduction in all-cause mortality observed among patients with obesity and co-occurring autoimmune disease is a striking finding that demands our attention,” said Fatima Cody Stanford, M.D., M.P.H., M.P.A., M.B.A., an obesity medicine physician scientist at Massachusetts General Hospital and Harvard Medical School who was not involved in the research.
Stanford added that the findings align with what clinicians had long suspected: “the benefits of GLP-1 receptor agonists extend well beyond blood sugar control and weight loss and may fundamentally alter the disease trajectory for some of our highest-risk patients.”
This view is supported by a growing body of evidence on GLP-1’s anti-inflammatory mechanisms GLP-1 medicines improve health through reduction of blood glucose and body weight, by attenuation of inflammation, and via direct activation of receptors in target tissues. It is this anti-inflammatory action that researchers believe may be particularly relevant in autoimmune patients, whose underlying conditions keep the immune system in a state of chronic activation.
GLP-1 drugs and clot risk: a widening picture
Earlier research had already begun to hint at clot-related benefits in specific subgroups. Data presented at the Hemostasis and Thrombosis Research Society 2025 Scientific Symposium showed that women who received a GLP-1 agonist for one year after initiation of hormone therapy had a significantly lower rate of arterial thromboembolism and venous thromboembolism compared with those not on a GLP-1. Separate analyses have examined GLP-1’s potential role in reducing thrombotic events in patients with breast cancer undergoing hormonal therapy.
However, specialists urge caution about what these results do and do not mean clinically. As one haematologist noted in a commentary published by the American Society of Hematology: “By no means does this study suggest a patient can substitute a GLP-1 agonist for an anticoagulant to prevent blood clots.”
A broader therapeutic horizon
GLP-1 therapy has shown benefit in improving atherothrombosis markers, including inflammation, endothelial dysfunction, and clotting. The drug class has already expanded well beyond its original indications. In 2024, semaglutide became the first weight loss drug to also be approved for the reduction of risk of serious cardiovascular events in patients with cardiovascular disease and obesity. In late 2024, tirzepatide became the first GLP-1 and the first medication to be approved for sleep apnoea. In August 2025, subcutaneous Wegovy became the first GLP-1 to be approved for metabolic dysfunction-associated steatohepatitis
Parallel efforts are now exploring new indications, including neurodegenerative and substance use disorders, metabolic liver disease, arthritis, Type 1 diabetes, and inflammatory bowel disease.
Caveats
The study has limitations that its authors acknowledge openly. Autoimmune diseases are highly diverse, and the primary analysis treated them as a broad group. Other factors, such as weight loss or improved blood sugar levels, may have contributed to the observed positive outcomes. More research is needed to investigate and evaluate the role of GLP-1-based medications as treatment and preventative therapy for obesity and autoimmune disease.
Still, for clinicians managing patients who carry the compounded burden of obesity and autoimmune disease, the findings offer a new lens through which to weigh treatment decisions. As Sheer put it: “For people who are overweight or living with obesity and an autoimmune disease, this study offers a hopeful signal that medications already in use today may be beneficial in reducing their risk of cardiovascular disease.”
